Extending the reach of peptide therapeutics

Developing unprecedented peptide therapeutic modalities

About

About

Peptide Logic is a biopharmaceutical company combining the advantages of synthetic peptides and recombinant antibodies to create transformative peptide-antibody conjugates (PACs) for pain and other selected therapeutic areas.

Sience

Science

The therapeutic utility of peptides has expanded over time from short-acting analogs of naturally-occurring peptides to long-acting peptides, bi-functional peptides, recombinant fusion proteins, proteinomimetics and, most recently, semi-synthetic peptide-antibody conjugates (PACs).

Technology

Technology

To create the peptide-based drugs of the future, we are building the most comprehensive and versatile peptide technology platform through in-licensing, partnerships and internal development.

Pipeline

We are developing multi-product pipelines of first-in-class peptide-based drugs in pain and other selected therapeutic areas.

Team

R&D Team

Our discovery is led by a team of seasoned professionals with advanced expertise in peptide therapeutics and peptide-antibody conjugates.

Pierre Riviere

Founder & CEO

Glenn Croston

Discovery Pharmacology

Regent Laporte

Translational Pharmacology

Careers

Be part of the founding team of an exciting new company developing transformative new therapeutics for pain and other selected therapeutic areas. We are specifically looking for highly motivated individuals seeking to make impactful contributions to the success of the company and the improvement of patient care. As a growing company, we offer the opportunity for personal development and growth, combined with competitive benefits and incentives.

To apply for a posted position, please email your resume to info@peptidelogic.com along with a cover letter outlining how you are a fit for the position.

OPEN POSITIONS

________________________________________________________________

careers

News

News

October 4, 2019

Peptide Logic Awarded $ 3.0 Million Grant to Develop Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA‑SSTR4) Agonists for Pain

August 15, 2018

Peptide Logic Awarded A $ 2.9 Million SBIR Phase II Grant To Develop Peripherally-Restricted And Long-Acting Kappa-Opioid Receptor (LA-KOR) Agonists For Moderate-To-Severe Pain

Contact

Pepide Logic

6185 Cornerstone Court E, Suite 112, San Diego, CA 92121.

Contact